Acepromazine, 136, 137t
  - drug combinations with, 140–41, 140t, 141t
  - equine preanesthetic sedative with, 363
  - geriatric patients premedication with, 277–78, 280t
  - induction with, 149
  - pediatric patients premedication with, 269, 270t
Acetaminophen, 352
Acupuncture, pain management with, 353–54
Acute pain, 326
Adaptive pain, management of, 347–50
  - alpha-2 agonists for, 347–49
  - local anesthetics for, 349–50, 350f
  - NMDA receptor antagonists for, 348–49
  - nonsteroidal antiinflammatory drugs for, 347
  - opioids for, 348, 349f, 349t
  - tramadol for, 348
Addison's disease. See Hypoadrenocorticism
ADH. See Antidiuretic hormone
Adjunctive analgesics drugs, 16
Adjustable pressure limiting valve (APL valve), 76
ADT. See Advanced diagnostic testing
Advanced diagnostic testing (ADT), 21–22
  - blood glucose, 22
  - BUN serum test, 22, 249
  - complete blood count, 22
  - complications with, 168
  - creatinine serum test, 22, 249
  - full chemistry profile, 22
  - packed cell volume, 22
  - total plasma protein, 22
  - urine specific gravity, 22
Advance life support, cardiopulmonary/cerebral resuscitation with, 178
Afferent nerve fibers, 327–28, 328t
A-fib. See Atrial fibrillation
Afterload, 5
Agent dose calculation, 30–31, 31t
Agent strength percent solution calculations, 30
Airway maintenance, 57–70
  - cleaning and sterilization with, 67–70
  - complications with, 67, 68t
  - endotracheal tubes v. facemask for, 58t
  - extubation for, 66–67, 67t
  - three-way stopcock with, 66, 67t
  - intubation for, 63–66, 63f
    - assistant holds head for, 63, 63f
    - cuff inflation guidelines with, 65t
    - guidelines for success with, 63t
    - laryngoscopy with, 64t
    - placement confirmation with, 66t
    - tube tie with, 66t
  - intubation supplies for, 61–63
    - laryngoscopes, 61–62, 62f
    - stylet and guide tubes, 62–63, 62f
  - selecting appropriate tube for, 60–61
  - special endotracheal tubes for, 58–59, 59f
  - tube design for, 59–60, 60f
  - tube storage with, 67–70, 69f
  - types of endotracheal tubes for, 57–58, 58f
Airway management, cardiopulmonary/cerebral resuscitation with, 175
Airway obstruction
  - anesthesia complicated by, 170–71
  - capnograph showing, 117f
Alanine aminotransferase (ALT), 22
Albumin, 124–25
Alfaxalone, pediatric patients induction with, 270t, 271
Alkaline phosphatase serum tests, 22
Alpha-2 agonists, 137–38
  - adaptive pain management with, 347–48
  - cardiovascular effects from, 215t
  - liver disease pharmacology with, 259–60
  - pediatric patients premedication with, 269
  - renal disease anesthesia with, 251, 253t
ALT. See Alanine aminotransferase
Alveolar-capillary membrane, 8
Alveolar ventilation, 8, 9
Alveoli, 7, 8f
Amantadine, pain management with, 352
American Society of Anesthesiologists (ASA), 20
  - status, 20–21, 21f
Amidate. See Etomidate
Aminotransferases, 22
Analgesics, 16
  - recovering patient with, 165
Anatomic dead space, 9, 10f, 113
Anesthesia equipment, 71–84
  - anesthetic delivery, 73–75, 74f, 75f
blood pressure monitoring, 119–20
breathing systems, 80–84, 81f, 82f
fresh gas flow rates, 83
low-flow circle, 83–84
nonrebreathing, 81–83, 82f
rebreathing, 80–81, 81f
reservoir bag, 83
selection of, 84
semiclosed circle, 84
carbon dioxide removal, 75–76
APL valve, 76, 168
carbon dioxide absorber canister, 75, 168
one-way valves, 75–76
complications with, 168
correcting problems in, 80
delivering functional components, 71–76, 72f, 74f, 75f
oxygen delivery, 71–73, 72f
performing pressure test for, 78–79
troubleshooting after procedure with, 80
troubleshooting before procedure with, 77–78
breathing bags/circuit, 78
breathing system, 77
one-way valves, 77
oxygen supply, 77
sodalime canister, 77–78
WAG tubing/connections, 78
troubleshooting during procedure with, 79, 79f
vaporizers, 73–75, 74f, 75f
complications with, 168
waste anesthetic gas removal, 76–77, 76f
active system, 76–77, 76f
passive system, 76
Anesthesiologist Society of America (ASA)
heart disease patients classified by, 207t
physical status scale from, 85
Anesthetic depth monitoring, 101–3, 101f–103f
Capillary Refill Time in, 101–2, 102f
corneal reflex in, 101, 101f
esophageal stethoscope in, 102–3, 103f
jaw tone in, 101, 102f
mucus membrane color in, 101
palpation of arteries in, 102, 102f
palpebral reflex in, 101
position of eye in, 101
swallowing reflex in, 101
withdrawal reflex in, 101, 101f
Anesthetic record, 35–37, 36f
automated, 37
handwritten monitoring grid, 37
information included in, 35
legal document, 37
Antibiotics, 16
Anticholinergics, 136
  cardiovascular effects from, 215t
  pediatric patients premedication with, 269, 270t
  renal disease anesthesia with, 251, 253t
Antidiuretic hormone (ADH), 248–49
Aortic stenosis, 212, 214t
APC. See Atrial fibrillation premature complex
APL valve. See Adjustable pressure limiting valve
Apnea, anesthesia complicated by, 170
Arrhythmias, 5, 88
  anesthesia complicated by, 173
    supraventricular, 213, 217t
Arterial blood gases, 24
ASA. See Anesthesiologist Society of America
Aspartate aminotransferase (AST), 22
Aspiration, anesthesia complicated by, 169–70
AST. See Aspartate aminotransferase
Atelectasis, 8, 189
Atipamezole, cardiopulmonary/cerebral resuscitation
  with, 180t
Atracurium, neuromuscular blockade with, 199
Atrial fibrillation (A-fib), 91
Atrial fibrillation premature complex (APC), 91, 213
Atrial standstill, 217
Atrioventricular block (AV block), 4, 89–90, 89f
  1st degree, 89, 216, 217t
  2nd degree, 89, 89f, 216, 217t
  3rd degree, 90, 216–17, 217t
Atrioventricular node (AV node), 3
Atropine, 136, 137t
  cardiopulmonary/cerebral resuscitation with,
    178–79, 180t
  equine preanesthetic sedative with, 363
  geriatric doses for, 280t
  pediatric doses for, 270t
Auriculopalpebral nerve block, 374
AV block. See Atrioventricular block
AV node. See Atrioventricular node

BAG (butorphanol, acepromazine, glycopyrrolate), 140–41, 140f
Bain Coaxial system, 82, 82f
Bandage placement, 164
Barbiturates
  cerebral blood flow with injectable, 222
  induction with, 147–49
  liver disease pharmacology with, 260
  renal disease anesthesia with, 252, 253t
Base deficit, 93
Base excess (BE), 93
Basic minimum database (BMD), 21
BE. See Base excess
Benzodiazepines, 136–37
  cardiovascular effects from, 215t
  cerebral blood flow with injectable, 222
  geriatric patients premedication with, 277, 280t
  induction with, 144–45
liver disease pharmacology with, 259–60
pediatric patients premedication with, 269, 270t
renal disease anesthesia with, 251, 253t

Bicarbonate level (HCO₃), 93

Blood gas analysis, 91–93
components of, 92–93
- base excess/base deficit, 93
- bicarbonate level, 93
- end-tidal carbon dioxide, 92
- oxygen saturation, 92–93
- partial pressure of carbon dioxide, 92
- partial pressure of oxygen, 92
- pH, 92
errors in sampling with, 93
physiology with, 92
sample collection for, 93

Blood glucose, 22

Blood pressure, 5–7
diastolic, 5, 106, 107t
direct (invasive) monitoring of, 107–10, 109f
- arterial catheter used for, 108
- selecting catheter site for, 108
- troubleshooting, 109–10
- waveform interpretation for, 108, 109f
factors determining, 106, 106f
cardiac output as, 106, 106f
heart rate as, 106, 106f
stroke volume as, 106, 106f
total peripheral resistance as, 106
indirect (noninvasive) monitoring of, 110–12, 111f
cuff selection for, 110, 111f
Doppler ultrasonography for, 111
oscillometric methods for, 111
photoplethysmographic methods for, 111
Ravi-Ricci return-to-flow principle with, 111, 112

maintenance of monitoring equipment for, 119–20
mean, 5
monitoring of, 105–12
normal values for, 106, 107t
systolic, 5, 6, 106, 107t

Blood products, 130–32, 131f, 132f
cryoprecipitate, 130
fresh frozen plasma, 130
human immunoglobulin, 130–31, 132f
packed red blood cells, 130
whole blood, 130, 130f

Blood typing, 131–32, 132f
cats, 132, 132f

Blood urea nitrogen (BUN), 22, 249

Blunt force trauma, 296
BMD. See Basic minimum database
BMG (butorphanol, midazolam, glycopyrrolate), 140f

Body temperature
- hyperthermia and, 99–100
- hypothermia and, 98–99
monitoring of, 97–101
normal, 98
recovering patient's, 163

heating elements for, 163, 163f

Brachycephalic breeds, 231–32, 231f, 232f
Bradycarrhythmias, 216, 217t
Bradycardia, sinus, 88–89
Breathing, cardiopulmonary/cerebral resuscitation with, 175–76
Breathing systems, 80–84, 81f, 82f
- fresh gas flow rates, 83
- low-flow circle, 83–84
- nonrebreathing, 81–83, 82f
- rebreathing, 80–81, 81f
- reservoir bag, 83
- selection of, 84
- semiclosed circle, 84

Bronchi, 7
Bronchioles, 7
Buccal mucosal bleeding time, 23
BUN. See Blood urea nitrogen
BUN serum test, 22, 249
Buprenorphine, 139
pediatric doses for, 270t
Burn injuries, 295–96, 296f
Butorphanol, 137t
drug combinations with, 140, 140t, 141t
equine preanesthetic sedative with, 363–64
geriatric doses for, 280t
Butyrophenones, 136, 137t
cerebral blood flow with injectable, 222

Calcium gluconate, cardiopulmonary/cerebral resuscitation with, 180t

Capillaries, 8
Capillary Refill Time (CRT), 101–2, 102f

Capnograph, 113, 115f–118f, 119t
airway obstruction in, 117f
artifacts due to strong heart beat in, 117f
changes in, 119t
CO₂ rebreathing in, 117f
hyperventilation in, 116f
hypoventilation in, 115f
normal, 115f
spontaneous breaths during mechanical ventilation in, 116f

Capnography, 112–13

Capnometer, 113–14

Carbon dioxide removal equipment, 75–76
APL valve, 76, 168
carbon dioxide absorber canister, 75, 168
one-way valves, 75–76
Cardiac disease patients, 205–17
aortic stenosis with, 212, 214t
atrial premature contractions with, 213
atrial standstill with, 217
AV block, 1st degree with, 216, 217t
AV block, 2nd degree with, 216, 217t
AV block, 3rd degree with, 216–17, 217t
bradyarrhythmias with, 216, 217t
classification of, 206–7, 207t
dilated cardiomyopathy with, 208–9, 214t
heart failure with, 207–8, 208f
heartworm disease with, 212–13, 214t
hypertrophic cardiomyopathy with, 209–10, 214t
measures to optimize outcome for, 205–6
 balanced anesthesia, 205–6
 IV fluid support, 206
 perioperative blood work evaluation, 206
 premedications, 205
 preoxygenation, 206
 reduce stress, 205
 ventilatory support, 206
mitral regurgitation with, 210f
mitral valve insufficiency with, 210, 210f, 214t
patent ductus arteriosus with, 214t
patent ductus arteriosus with, 210–11
perianesthetic arrhythmias with, 213–16
pulmonic stenosis with, 211–12, 214t
subaortic stenosis with, 210f
subpulmonary arrhythmias with, 213, 217t
ventricular premature contractions with, 213, 217t
ventricular tachycardia with, 217t

Cardiac output, 106, 106f
capnography for, 112
Cardiogenic shock, fluid therapy contraindicated for, 130
Cardiopulmonary arrest (CPA), 174–75
equipment for, 175–76
reasons for, 175
signs of, 174–75
Cardiopulmonary/cerebral resuscitation (CPCR), 175–78
advance life support with, 178
airway management in, 175
breathing in, 175–76
circulation in, 176–78
complications with, 183–84
defibrillation with, 181–82
drugs used with, 178–79, 180t
 atipamezole, 180t
 atropine, 178–79, 180t
calcium gluconate, 180t
dobutamine, 180t
dopamine, 180t
epinephrine, 179, 180t
flumazenil, 180t
furosemide, 180t
glycopyrrolate, 178–79, 180t
lidocaine, 179, 180t
naloxone, 180t
sodium bicarbonate, 180t
vasopressin, 179, 180t
electrocardiography as monitor during, 181
fluid therapy with, 182
open chest, 178–84
prolonged life support with, 182–83
routes of drugs administration during, 179–81
central venous, 179
intracardiac, 181
intralingual, 181
intraosseous, 179
intratracheal, 179–81
peripheral venous, 179
Cardiovascular drugs, 16
Cardiovascular system, 3–7
afterload with, 5
anatomy/physiology for, 3–4
anesthesia complication of, 172–74
anesthetic agents effects on, 215t
arrhythmias with, 5
atrioventricular node of, 3
blood pressure with, 5–7
cardiac cycle of, 4
contractility with, 5
determining heart rate from ECG, 4–7
electrical activity of, 4
 AV conduction block, 4
electrocardiogram, 4
P-R interval, 4
QRS complex, 4
Q-T interval, 4
T wave, 4
equine anesthesia and effects on, 360
preanesthetic workup exam for, 17–18, 25f
sino-atrial node of, 3
volume status with, 7
Cataract removal, 202
Catheterization, 49–55
arterial catheter for, 51, 51f, 108
blood pressure monitoring with, 108
care for, 54–55
catheter placement/stabilization for, 51–52, 52f, 53f
catheter size/type for, 49–50, 50f
multilumen, 49–50, 50f
through needle, 49
over needle, 49
choosing correct catheter for, 50
double lumen catheter for, 50–51, 50f
prepping site for, 52–54, 52f–54f
quadruple lumen catheter for, 50–51
single lumen central catheter for, 50, 54f
supplies for, 53–54
triple lumen catheter for, 50–51
troubleshooting, 54
urinary, recovering patient with, 164–65
vascular access ports for, 50
venous catheter for, 51
Cats
blood typing with, 132, 132f
intravenous potassium supplementation for, 129t
laryngospasm in, 64t
PRBC for, 133f
selecting appropriate tube for intubation of, 61
signs of acute pain in, 335f
Caudal block, 375
CBC. See Complete blood count
Central venous pressure (CVP), 7
Cerebral blood flow, 219–20
injectable anesthetics for, 221–23
Cesarean section techniques, 283–90
anesthetic drug selection for, 284–88, 287t
induction agents, 285–86, 287t
maintenance agents, 286–88, 287t
preanesthetic agents, 284–85, 287t
anesthetic technique for, 288–89, 288f
resuscitation of newborn with, 289–90, 289f, 290f
Chamber, inhalant induction procedures using, 143–44, 144f
Chemistry profile, 22
Chemotherapy drugs, 16
Chronic pain, 326
Cisatracurium, cerebral blood flow with injectable, 222–23
Coagulation profile, 22
Colloids, 124
Complete blood count (CBC), 22
Compliance, 189
Complications, 167–84
cardiopulmonary arrest, 174–75
equipment for, 175–76
reasons for, 175
signs of, 174–75
cardiopulmonary/cerebral resuscitation, 183–84
glucose, 184
hyperthermia, 183–84
cardiovascular, 172–74
arrhythmias, 173
hypertension, 173
hypotension, 172
tachycardia, 173
ventricular fibrillation, 173–74
ventricular premature complexes, 173–74
ventricular tachycardia, 173–74
equipment, 168–69
APL valve complications, 168
carbon dioxide absorber exhaustion, 168
endotracheal tube complications, 67, 68t, 168
vaporizer complications, 168
ferrets, rodents, and rabbits with, 322
human error as cause of, 167
physiologic, 169–72
airway obstruction, 170–71
apnea, 170
aspiration, 169–70
excitation, 169
hyperventilation, 172
hypoverilation, 171
hypoxemia, 172
hypoxia, 172
laryngospasm, 171
prolonged recovery from anesthesia, 184
Conjunctival flap, 202
positioning for, 203f
Constant rate infusion (CRI), 33
Contractility, 5
Controlled substances, record keeping for, 37–39, 39f
Controlled ventilation, 189
Coneal reflex, 101, 101f
Cornual nerve block, 374–75, 375f
COX inhibition. See Cyclooxygenase inhibition
CPA. See Cardiopulmonary arrest
CPCR. See Cardiopulmonary/cerebral resuscitation
Creatinine serum test, 22, 249
CRI. See Constant rate infusion
CRT. See Capillary Refill Time
Cryoprecipitate, 130
Crystalloids, 124
Cushing reflex, 220–21
Cushing's disease. See Hyperadrenocorticism
CVP. See Central venous pressure
Cyclohexamines, induction with, 145–46
Cyclooxygenase inhibition (COX inhibition), renal
disease anesthesia with, 254, 254t
DABP. See Direct arterial blood pressure monitoring
DACVA. See Diplomates of the American College of Veterinary Anesthesiologists
Dead space ventilation, 9, 10f
Defibrillation, cardiopulmonary/cerebral resuscitation with, 181–82
Dehydration
clinical signs for, 126t
replacement requirement calculation for, 126f
Demerol. See Meperidine
Desaturation, 10, 233–34
Desflurane, 158
inhalant anesthetics for ICP with, 223
minimum alveolar concentration of, 154t
vaporization pressure of, 155t
Detomidine, equine preanesthetic sedative with, 362
Dexmedetomidine. See Medetomidine
Dextran, 125
Diabetes mellitus, 239–40
Diagnostics imaging, 24
radiography, 24
ultrasound, 24
Diastolic blood pressure, 5, 106, 107t
Diazepam (Valium), 136–37, 137t
  cerebral blood flow with injectable, 222
  equine preanesthetic sedative with, 363
  geriatric doses for, 280t
  induction with, 144–45, 147t, 149, 150t
  liver disease pharmacology with, 260
Dilated cardiomyopathy, 208–9, 214t
Diplomates of the American College of Veterinary
Anesthesiologists (DACVA), monitoring guidelines
from, 85
Diprivan. See Propofol
Direct arterial blood pressure monitoring (DABP),
107–10, 109f
  arterial catheter used for, 108
  selecting catheter site for, 108
  troubleshooting, 109–10
    inaccurate readings, 110
    sudden change in pressure, 110
  waveform amplification, 110
  waveform dampening/loss, 109–10
  waveform not visible, 110
  waveform interpretation for, 108, 109f
Dissociative drugs, 138–39
  cardiovascular effects from, 215t
  liver disease pharmacology with, 260–61
Dobutamine, cardiopulmonary/cerebral resuscitation
with, 180t
Dogs
  blood typing with, 132, 132f
  intravenous potassium supplementation for, 129t
  larynx of, 64f
  PRBC for, 133f
  selecting appropriate tube for intubation of, 61
  signs of acute pain in, 335f
Dopamine, cardiopulmonary/cerebral resuscitation
with, 180t
Doppler ultrasonography, 111
Dorsal horn
  anatomy of, 328–29, 329f
  neurochemistry of, 329–30
Dose calculation, 30–31, 31t
Drug calculation, 31–32
ECG. See Electrocardiogram
Elastic recoil, 8
Electrocardiogram (ECG), 4, 24
  applications for monitoring of, 86
  arrhythmia in, 88
  atrial fibrillation in, 91
  atrial fibrillation premature complex in, 91
  atrioventricular block in, 89–90, 89f
  cardiopulmonary/cerebral resuscitation monitored
    with, 181
  determining heart rate from, 4–7
  hyperkalemia indicated by, 129
  inaccurate data with, 87
  interpreting data from, 87
  monitoring information from, 86
    P wave, 86
    QRS complex, 86
    T wave, 86, 87f
  monitoring process for, 86–87
  monitoring with, 86–91
  physiology with, 86
  sinus bradycardia in, 88–89
  sinus tachycardia in, 88, 88f
  ventricular fibrillation in, 91
  ventricular premature contraction in, 90
  ventricular tachycardia in, 90–91, 90f
Electrolyte abnormalities, 127–30
  hypochloremia/hyperchloremia, 127
  hypokalemia/hyperkalemia, 128–30, 129t
  hyponatremia/hypernatremia, 127–28, 128f
Electroretinogram (ERG), anesthesia for, 201
Emergencies, 167–84. See also Complications; Trauma
  patients
  cardiopulmonary arrest, 174–75
    equipment for, 175–76
    reasons for, 175
    signs of, 174–75
  cardiopulmonary/cerebral resuscitation, 175–78
    advance life support with, 178
    airway management in, 175
    breathing in, 175–76
    circulation in, 176–78
    complications with, 183–84
    defibrillation with, 181–82
    drugs used with, 178–79, 180t
    electrocardiography as monitor during, 181
    fluid therapy with, 182
    open chest, 178–84
    prolonged life support with, 182–83
    routes of drugs administration during, 179–81
  crash protocols, 174–75
    equipment for, 174–75
  ferrets, rodents, and rabbits in, 322
  nontrauma, 301–10
    foreign bodies/obstructions, 305–7
    gastric dilatation-volvulus, 303–5, 304f
    intervertebral disk disease, 307–9, 308f,
      309f
    pyometra, 310
    shock, 301–3
    urethral obstruction, 309–10
Endocrine diseases, 239–43
  diabetes mellitus, 239–40
hyperadrenocorticism (Cushing’s disease), 241–42, 241f
hyperthyroidism, 242–43
hypoadrenocorticism (Addison’s disease), 242
hypothyroidism, 243
insulinoma, 240

Endocrine system
preanesthetic workup exam for, 20, 25f
testing for, 24

Endotracheal tubes, 57–70
cleaning and sterilization of, 67–70
complications with, 67, 68t, 168
design for, 59–60, 60f
extubation with, 66–67, 67t
patient recovery and, 165–66
three-way stopcock with, 66, 67t
facemask v., 58t
intubation with, 63–66, 63f
assistant holds head for, 63, 63f
cuff inflation guidelines with, 65t
guidelines for success with, 63t
laryngospasm with, 64t
placement confirmation with, 66t
tube tie with, 66t
proper/improper lengths of, 114f
selecting appropriate tube for, 60–61
special, 58–59, 59f
storage of, 67–70, 69f
supplies for intubation with, 61–63
laryngoscopes, 61–62, 62f
stylet and guide tubes, 62–63, 62f
types of, 57–58, 58f

End-tidal carbon dioxide (ETCO₂), 92
anatomic dead space with, 113
capnograph for monitoring of, 113, 115f–118f, 119t
airway obstruction in, 117f
artifacts due to strong heart beat in, 117f
CO₂ rebreathing in, 117f
hyperventilation in, 116f
hypoventilation in, 115f
normal, 115f
spontaneous breaths during mechanical ventilation in, 116f
capnometer for monitoring of, 113–14
causes for change in, 119t
equine anesthesia maintenance with, 369
mainstream (nondiverting) monitor for, 114
maintenance of monitoring equipment for, 119–20
mechanical dead space with, 113
monitoring of, 113–20
monitor types for, 113–14
primary methods for monitoring of, 113
infrared light absorption, 113
mass spectroscopy, 113
sidestream (diverting) monitor for, 114–19

Enucleation, 202
Epidural block, 377–78
Epinephrine, cardiopulmonary/cerebral resuscitation with, 179, 180t

Equine anesthesia, 357–71
cardiovascular effects with drugs for, 360
different circumstances with drugs for, 359–60
dose range with drugs for, 359
five phases of, 360
induction phase, 360
maintenance phase, 360
postanesthetic phase, 360
preanesthetic phase, 360
recovery phase, 360
four pillars of, 359–60
assessment, 358, 358f
familiarity, 358–59
planning, 359
readiness, 358, 359f
individual differences with drugs for, 359
induction phase of, 364–65
guaifenesin, 364
diazepam, 364–65
tolazoline-zolazepam, 365
maintenance phase of, 365–70
balanced anesthesia in, 366
diagonal CO₂ in, 369
hypotension treatment for, 367–68
inhalant anesthetics for, 365
monitoring in, 366–67
padding/positioning in, 366, 366f
pulse oximetry in, 369
respiration in, 368–69
TIVA in, 365–66
ventilation in, 369
postanesthetic phase in, 371
preanesthetic phase of, 360–64
emptying GI tract in, 361
laboratory results in, 361
patient physical examination in, 360–61
sedative in, 360–64
preanesthetic sedative for, 362–64
acepromazine, 363
atropine, 363
butorphanol, 363–64
detomidine, 362
diazepam, 363
medetomidine (Dexmedetomidine), 363
morphine, 364
xylazine, 362
recovery phase of, 370–71
anesthetic agent elimination in, 370
antagonists in, 370–71
oxygenation in, 371
patent airway in, 371
sedation in, 370
Equipment. See Anesthesia equipment
ERG. See Electroretinogram
Esophageal stethoscope, 102–3, 103f
ETCO₂. See End-tidal carbon dioxide
Etomidate (Amidate)
  cardiovascular effects from, 215t
  cerebral blood flow with injectable, 222
  induction with, 147, 147t, 150t
  liver disease pharmacology with, 260
  pediatric patients induction with, 270t, 271
Excel worksheet
  drug calculation with, 31–32
  fluid calculation with, 32, 32t
Excitation, anesthesia complicated by, 169
Extraocular procedures, anesthesia for, 201
Extubation, 66–67, 67t
  patient recovery and, 165–66
  three-way stopcock with, 66, 67t
Fentanyl, 137t, 139
  induction for respiratory-challenged patients with, 231t
  induction with, 149, 150t
Ferrets, 313–17
  anesthesia induction, care and support for, 314–15
  anesthesia preparation for, 313–14
  anesthesia recovery with, 316
  emergency considerations for, 322
  fluid therapy plan for, 316
  monitoring during anesthesia for, 316
FFP. See Fresh frozen plasma
Fluid calculation, 32, 32t
Fluid drip rates calculation, 31–32
Fluids
  classifications of, 124–25
    albumin, 124–25
    colloids, 124
    crystalloids, 124
    dextan, 125
    hetastarch, 125
    transcellular, 123
Fluid therapy, 123–34
  cardiogenic shock with, 130
  cardiopulmonary/cerebral resuscitation with, 182
  electrolyte abnormalities requiring, 127–30
    hypochloremia/hyperchloremia, 127
    hypokalemia/hyperkalemia, 128–30, 129t
    hyponatremia/hypernatremia, 127–28, 128f
  ferrets, plan for, 316
  hydration deficit replacement requirement calculation for, 126f
  hypovolemic shock requiring, 129
  long-term, 126
  maintenance, 125–26
  obstructive shock with, 130
  replacement, 126–27, 126f, 126t
  resuscitation, 127
  types of, 125–27
Flumazenil
  cardiopulmonary/cerebral resuscitation with, 180t
  geriatric doses for, 280t
  pediatric doses for, 270t
Foreign bodies/obstructions, 305–7
FRC. See Functional residual capacity
Fresh frozen plasma (FFP), 130
Functional residual capacity (FRC), 9, 189
Furosemide, cardiopulmonary/cerebral resuscitation with, 180t
Gabapentin, pain management with, 352
Gag reflex, 160
Gastric dilatation-volvulus (GDV), 303–5, 304f
Gastrointestinal system, preanesthetic workup exam for, 19, 25f
GDV. See Gastric dilatation-volvulus
Geriatric patients, 275–81
  induction for, 278–79, 280t
  alfaxalone, 279, 280t
  etomidate, 278–79, 280t
  ketamine, 279, 280t
  propofol, 278, 280t
  maintenance for, 279
  monitoring for, 279–81, 280f
  physiology of, 275–76
  preanesthesia preparation for, 276
  premedication for, 276–78
    acepromazine, 277–78, 280t
    alpha-2 agonists, 278
    anticholinergics, 278, 280t
    benzodiazepine, 277, 280t
    opioids, 277, 280t
  recovery for, 281
GFR. See Glomerular filtration rate
Glomerular filtration rate (GFR), 249
Glycopyrrolate, 136, 137t
  cardiopulmonary/cerebral resuscitation with, 178–79, 180t
  drug combinations with, 140, 140t, 141t
  geriatric doses for, 280t
  pediatric doses for, 270t
Guaiifenesin, equine induction phase with, 364
HAG (hydromorphone, acepromazine, glycopyrrolate), 141
Halothane, 156–57
  cardiovascular effects from, 215t
  inhalant anesthetics for ICP with, 223
  minimum alveolar concentration of, 154t
  vaporization pressure of, 153t
HCO₃. See Bicarbonate level
Head trauma, 219–24
  MRI of, 220f
Heart. See also Cardiovascular system
  anatomy/physiology of, 3–4
  atrioventricular node of, 3
  cardiac cycle of, 4
  ECG—determining rate of, 4–7
  mitral valve, 4
  murmurs, 4
  normal blood flow through, 208f
  sino-atrial node of, 3
  tricuspid valve, 4
  volume status with, 7
Heart failure, 207–8, 208f
Heart rate, 106, 106f
Heartworm disease, 212–13, 214t
Hepatic system, preanesthetic workup exam for, 19, 25f
Hetastarch, 125
Hoffman elimination, 199
Human immunoglobulin (IGg), 130–31, 132f
Hyaluronic acid, 353
Hydromorphone, 137t, 139
  drug combinations with, 140t, 141, 141t
  induction for respiratory-challenged patients with, 231t
  induction with, 149, 150t
Hyperadrenocorticism (Cushing’s disease), 241–42, 241f
Hypercarbia, 10
Hypertension, anesthesia complicated by, 173
Hyperthermia, 99–100
  causes of, 100
  malignant, 100
  treatment of, 100
Hyperthyroidism, 242–43
Hypertrophic cardiomyopathy, 209–10, 214t
Hyperventilation, 188–89
  anesthesia complicated by, 171
  capnograph showing, 115f
Hypovolemic shock, 129
Hypoxemia, 10, 189
  anesthesia complicated by, 172
Hypoxia, anesthesia complicated by, 172
ICP. See Intercranial pressure
IGg. See Human immunoglobulin
Induction drugs, 143–50
  inhalant induction procedures for, 143–44, 144f
    chamber, 143–44, 144f
    mask, 143, 144f
  injectable induction agents, 144–47, 147t
    acepromazine, 149
    barbiturates, 147–49
    benzodiazepines, 144–45
    cyclohexamines, 145–46
    diazepam, 144–45, 147t, 149, 150t
    etomidate, 147, 147t, 150t
    fentanyl, 149, 150t
    hydromorphone, 149, 150t
    ketamine (ketaset, vetalar, ketalean), 145, 147t, 150t
    meperidine, 149
    methylated oxybarbiturate (methohexital), 148–49
    midazolam (versed), 145, 147t, 149, 150t
    morphine, 149
    neuroleptanalgesia, 149–50
    opioids, 149
    oxymorphone, 149, 150t
    propofol, 146–47, 147t, 150t
    thiobarbiturate (thiopental), 148–49
    tiletamine (Telazol), 145–46, 147t, 150t
    zolazepam, 145, 147t, 150t
Infrared light absorption, 113
Inhalant anesthetics, 153–58
  characteristics of ideal, 153–54
    desflurane, 158
    minimum alveolar concentration of, 154t
    vaporization pressure of, 155t
    halothane, 156–57
    minimum alveolar concentration of, 154t
    vaporization pressure of, 155t
    history, 153
    induction procedures with, 143–44, 144f
Hypothermia, 98–99
  active patient warming for, 99
  monitoring body temperature with, 98
  prevention of, 98–99
Hypothyroidism, 243
Hypoventilation, 188–89
  anesthesia complicated by, 171
  capnograph showing, 115f
Hypovolemic shock, 129
Hypoxemia, 10, 189
  anesthesia complicated by, 172
Hypoxia, anesthesia complicated by, 172
Hypothyroidism, 243
Hypertrophic cardiomyopathy, 209–10, 214t
Hyperventilation, 188
  anesthesia complicated by, 172
  capnograph showing, 116f
Hypoadrenocorticism (Addison's disease), 242
Hypocapnia, 18
Hyperventilation, 188
  anesthesia complicated by, 172
  capnograph showing, 115f
Hypoadrenocorticism (Addison's disease), 242
Hypocapnia, 188
Hypochloremia/hyperchloremia, 127
  cause of, 127
  treatment of, 128, 128f
Hypokalemia/hyperkalemia, 128–30, 129t
  clinical signs of, 128–29
  ECG changes indicating, 129
  treatment of, 129, 129t
Hyponatremia/hypernatremia, 127–28, 128f
  clinical signs of, 127–28
  fluid rate calculation for correction of, 128f
  treatment of, 128, 128f
Hypotension
  anesthesia complicated by, 172
  treatment for equine with, 367–68
iso\textit{flurane}, 157
  minimum alveolar concentration of, 154t
  vaporization pressure of, 155t
  mechanism of action for, 154
  minimum alveolar concentration for, 154–55, 154t
  desflurane, 154t
  halothane, 154t
  isoflurane, 154t
  nitrous oxide, 154t
  sevoflurane, 154t
nitrous oxide, 156
  minimum alveolar concentration of, 156
pharmacokinetics of, 154
sevoflurane, 157–58, 157f
  minimum alveolar concentration of, 154t
  vaporization pressure of, 155t
solubility coefficient of, 155, 155t
  vaporization pressure of, 155, 155t
desflurane, 155t
halothane, 155t
isoflurane, 155t
sevoflurane, 155t

Inspiratory to Expiratory Ratio (I:E ratio), 190, 190f, 191

Insulin, 17
Insulinoma, 240

Integument system, preanesthetic workup exam for, 19–20, 25f

Intercranial pressure (ICP), 219–24
  anesthetic agents effect on, 221
  anesthetics management for, 223–24
  autoregulation with, 219–20
  cerebral blood flow with, 219–20
  CO2 and O2’s effect on, 221
  Cushing reflex with, 220–21
  factors causing increase in, 221
  inhalant anesthetics for, 223
    desflurane, 223
    halothane, 223
    isoflurane, 223
    nitrous oxide, 223
    sevoflurane, 223
  injectable anesthetics for, 221–23
    barbiturates, 222
    benzodiazepine, 222
    butyrophenone, 222
    cisatracurium, 222–23
    diazepam, 222
    etomidate, 222
    ketamine, 222
    lidocaine, 222
    midazolam, 222
    phenothiazine, 222
    propofol, 222
    vecuronium, 222–23
  recovery for anesthetics used for, 224

Intermittent positive pressure ventilation, 188
Interstitial edema, 123
Interstitium, 123
Intervertebral disk disease (IVDD), 307–9, 308f, 309f
Intracellular compartment, 123
Intraocular pressure (IP), determinants of, 195–96, 196t
Intraocular procedures
  anesthesia for, 202
  positioning for, 202–3, 203f

Intravenous access, 49–55
  arterial catheter for, 51, 51f
  cardiac disease patient outcome with, 206
  care for, 54–55
  catheter placement/stabilization for, 51–52, 52f, 53f
  catheter size/type for, 49–50, 50f
    multilumen, 49–50, 50f
    through needle, 49
    over needle, 49
  choosing correct catheter for, 50
  double lumen catheter for, 50–51, 50f
  prepping site for, 52–54, 52f–54f
  quadruple lumen catheter for, 50–51
  single lumen central catheter for, 50, 54f
  supplies for, 53–54
  triple lumen catheter for, 50–51
  troubleshooting, 54
  vascular access ports for, 50
  venous catheter for, 51

Intubation, 63–66, 63f
  assistant holds head for, 63, 63f
  cuff inflation guidelines with, 65t
  guidelines for success with, 63t
  laryngospasm with, 64t
  placement confirmation with, 66t
  tube tie with, 66t

IP. See Intraocular pressure

Isoflurane, 157
  cardiovascular effects from, 215t
  inhalant anesthetics for ICP with, 223
  minimum alveolar concentration of, 154t
  vaporization pressure of, 155t

IVDD. See Intervertebral disk disease

IV fluids. See also Intravenous access

Jaw tone, 101, 102f

JGA. See Juxtaglomerular apparatus

Juxtaglomerular apparatus (JGA), 246–47, 248f

KBAG (ketamine + BAG), 141, 141f

Ketalean. See Ketamine

Ketamine (Ketaset, Vetalar, Ketalean), 137t, 138–39
  cerebral blood flow with injectable, 222
  drug combinations with, 141, 141t
  equine induction phase with, 364–65
induction for respiratory-challenged patients with, 230t, 231t
induction with, 145, 147t, 150t
IV fluids with administration of, 33
pediatric patients induction with, 270, 270t
Ketaset. See Ketamine
KHAG (ketamine, hydromorphone, acepromazine, glycopyrrolate), 141, 141f
Kitty Magic, 141–42, 141t
Laryngoscopes, 61–62, 62f
Laryngospasm, 64t
anesthesia complicated by, 171
Lasix, percent solution calculations, 30
Lidocaine
cardiopulmonary/cerebral resuscitation with, 179, 180t
cardiovascular effects from, 215t
cerebral blood flow with injectable, 222
induction for respiratory-challenged patients with, 230t, 231t
IV fluids with administration of, 33
liver disease pharmacology with, 261
percent solution calculations, 30
Liver, anatomy of, 257, 258f
Liver disease, 257–64
blood work to consider before anesthesia for, 257–58, 259t
conditions that affect liver, 261–64, 262f, 263f
drug protocol design for, 264
pharmacology for, 258–61
alpha-2 agonists, 259–60
barbiturates, 260
benzodiazepine, 259–60
diazepam, 260
dissociative drugs, 260–61
etomidate, 260
lidocaine, 261
nonsteroidal antiinflammatory drugs, 261
opioids, 260
phenothiazine, 259
propofol, 260
Low-flow circle system, 83–84
MAC. See Minimum alveolar concentration
Mainstream (nondiverting) monitor, 114
MAP. See Mean arterial pressure
Mapleson system, 81
Mask, inhalant induction procedures using, 143, 144f
Mass spectroscopy, 113
Mathematics, 29–34
administering agent by adding to IV fluids, 33
agent dose calculation, 30–31, 31t
agent strength percent solution calculations, 30
constant rate infusion, 33
Excel worksheet for drug calculation, 31–32
Excel worksheet for fluid calculation, 32, 32t
fluid drip rates calculation, 31–32
metric system, 29–30, 29t, 30t
percentages, 30
Mean arterial pressure (MAP), 5, 6
equation for, 106
Mechanical dead space, 10, 113
Medetomidine (Dexmedetomidine), 137t, 138
equine preanesthetic sedative with, 363
Meperidine (Demerol), induction with, 149
Methadone, 137t, 139
pediatric doses for, 270t
Methohexital. See Methylated oxybarbiturate
Methylated oxybarbiturate (Methohexital), induction with, 148–49
Metric system, 29–30, 29t, 30t
Minute volume, 9
Mitral regurgitation, 210f
Mitrval valve, 4
Mitrval valve insufficiency, 210, 210f, 214t
MM. See Mucus membrane color
Modified Jackson Rees system, 82
Monitoring, 85–120
anesthesia of ferrets, 316
anesthetic depth, 101–3, 101f–103f
Capillary Refill Time in, 101–2, 102f
corneal reflex in, 101, 101f
esophageal stethoscope in, 102–3, 103f
ejaw tone in, 101, 102f
mucus membrane color in, 101
palpation of arteries in, 102, 102f
palpebral reflex in, 101
position of eye in, 101
swallowing reflex in, 101
withdrawal reflex in, 101, 101f
ASA physical status scale, 85
blood gas analysis, 91–93
components of, 92–93
errors in sampling with, 93
physiology with, 92
sample collection for, 93
blood pressure, 105–12
direct (invasive) monitoring of, 107–10, 109f
factors determining, 106, 106f
indirect (noninvasive) monitoring of, 110–12, 111f
normal values for, 106, 107t
body temperature, 97–101
hyperthermia and, 99–100
hypothermia and, 98–99
normal, 98
capnography for, 112–13
DACVA guidelines for, 85
electrocardiogram, 86–91
applications for monitoring of, 86
arrhythmia in, 88
atrial fibrillation in, 91
atrioventricular block in, 89–90, 89f
cardiopulmonary/cerebral resuscitation with, 181
inaccurate data with, 87
interpreting data from, 87
monitoring information from, 86
monitoring process for, 86–87
physiology with, 86
sinus bradycardia in, 88–89
sinus tachycardia in, 88, 88f
ventricular fibrillation in, 91
ventricular premature contraction in, 90
ventricular tachycardia in, 90–91, 90f
capnograph for, 113, 115f–118f, 119t
capnometer for, 113–14
causes for change in, 119t
mainstream (nondverting) monitor for, 114
maintenance of monitoring equipment for, 119–20
monitor types for, 113–14
primary methods for, 113
sidestream (diverting) monitor for, 114–19
equine anesthesia, 366–67
hands-on, 101–3
neuromuscular blockade, 200–201, 200f
patient recovery, 162–63, 163f
pediatric patients, 272–73, 273f
pulse oximetry, 95–97
factors influencing accuracy of, 96
interpretation of data from, 97
patient assessment/treatment of decreased 
$\text{SpO}_2$ with, 97
physiology with, 95–96
types of, 96, 96f
working of, 95–96
record grid for, 37
Morphine, 137t, 139
drug combinations with, 140t, 141, 141t
equine preanesthetic sedative with, 364
induction for respiratory-challenged patients with, 230t
Naloxone, 139
cardiopulmonary/cerebral resuscitation with, 180t
geriatric doses for, 280t
pediatric doses for, 270t
Nerve stimulator, 200, 200f
Nervous system, preanesthetic workup exam for, 19, 25f
Neuroleptanalgesia, induction with, 149–50
Neuromuscular blockade (NMB), 198–201
drugs specific for, 199–200
atracurium, 199
monitoring of, 200–201, 200f
nerve stimulator for, 200, 200f
neuromuscular junction with, 199
reversal of, 201
types of, 199
depolarizing, 199
nondepolarizing, 199
use with ophthalmic procedures of, 198–99
ventilation with, 200
Neuropathic pain, 327
Nitrous oxide, 156
inhalant anesthetics for ICP with, 223
minimum alveolar concentration of, 156
renal disease anesthesia with, 252, 253t
NMB. See Neuromuscular blockade
NMDA receptor antagonists, adaptive pain management with, 348–49
Nonrebreathing system, 81–83, 82f
Bain Coaxial system, 82, 82f
flow rates for, 84
high pressure alarm for, 82
Mapleson system, 81
Modified Jackson Rees system, 82
Nonsteroidal antiinflammatory drugs (NSAID), 16
adaptive pain management with, 347
liver disease pharmacology with, 261
pain management with, 352
renal disease anesthesia with, 252–54, 253t
Nontrauma emergency patients, 301–10
foreign bodies/obstructions, 305–7
gastric dilatation-volvulus, 303–5, 304f
intervertebral disk disease, 307–9, 308f, 309f
pyometra, 310
shock, 301–3
urethral obstruction, 309–10
NSAID. See Nonsteroidal antiinflammatory drugs
Numorphan. See Oxymorphone
O’BAG (Old dog BAG), 140, 140f
Obstructive shock, 130
OCR. See Oculocardiac reflex

Ocular procedures
  anesthesia for, 202
  positioning for, 202–3, 203f
  recovery from procedures for, 203

Ocular trauma, 294

Oculocardiac reflex (OCR), 196

Ophthalmology patients, 195–203
  anesthesia for electroretinogram with, 201
  anesthesia for extraocular procedures for, 201
  anesthesia for ocular/intraocular procedures for, 202
  cataract removal, 202
  conjunctival flap, 202
 enucleation, 202
  general considerations for, 195
  induction/maintenance of anesthesia for, 197
  intraocular pressure determinants with, 195–96, 196t
  local blocks for, 198
  local infiltration of anesthetic with, 198
  retrobulbar block, 198
  neuromuscular blockade for, 198–201
  drugs specific for, 199–200
  monitoring of, 200–201, 200f
  neuromuscular junction with, 199
  reversal of, 201
  types of, 199
  use with ophthalmic procedures of, 198–99
  ventilation with, 200
  oculocardiac reflex with, 196
  positioning for procedures for, 202–3, 203f
  premedication for, 196–97
  recovery from procedures for, 203

Opioids, 139–40
  adaptive pain management with, 348, 349f, 349t
  cardiovascular effects from, 215t
  induction with, 149
  liver disease pharmacology with, 260
  pain management with, 352
  pediatric patients premedication with, 268–69, 270t
  renal disease anesthesia with, 251, 253t

Organophosphates, 17

Oscillometric methods, 111

Oxygen delivery equipment, 71–73, 72f
  compressed gas cylinder, 71
  flowmeter, 72–73, 72f
  oxygen concentrator, 71
  regulator, 71, 72f
  troubleshooting, 77

Oxygen saturation (SaO2), 92–93

Oxymorphone (Numorphan), 137t, 139
  drug combinations with, 140t, 141, 141t
  geriatric doses for, 280t
  induction for respiratory-challenged patients with, 231t
  induction with, 149, 150t
  pediatric doses for, 270t

Packed cell volume (PCV), 22

Packed red blood cells (PRBC), 130
  cat/dog, 133f

PaCO₂. See Partial pressure of carbon dioxide

Pain, 325–55
  adjunct therapies for, 353–54
    acupuncture, 353–54
    therapeutic laser, 354, 354f
    weight loss, 354
  assessment of, 333–43
    age differences for, 336
    behavioral signs for, 334–36, 337f
    breed differences for, 335
    chronic pain in, 342–43, 342f
    frequency of, 338–39
    general acute, 337–39, 337f
    individual characteristics for, 336
    painful conditions/procedures in, 339
    pain scoring systems for, 339–42, 340, 341f
    role of technician in, 334
    species differences for, 334–35, 335f
  classification of, 325–27, 346
    acute v. chronic, 326, 346
    adaptive v. maladaptive, 346
    physiologic v. pathologic, 325–26
    referred v. neuropathic, 327
    somatic v. visceral, 326–27
    gate control theory of, 330–31, 330f
    glucosamine-containing supplements for, 353
    hyaluronic acid for, 353
    joint/cartilage structure modifiers for, 353
    management of adaptive, 347–50
      alpha-2 agonists, 347–50
      local anesthetics, 349–50, 350f
      NMDA receptor antagonists, 348–49
      nonsteroidal antiinflammatory drugs, 347
      opioids, 348, 349f, 349t
      tramadol, 348
    management of maladaptive, 350–53
    management strategies for, 345–55
      central neuronal hypersensitization in, 345–46
      designing optimal, 345–46, 346t
      multimodal analgesia for, 345, 346t
      preemptive analgesia in, 346
      neuroendocrine signs of, 336–37
      pathways, 329–30, 327f
      afferent nerve fibers, 327–28, 328t
      ascending spinal tracts with, 330
      dorsal horn neurochemistry with, 329–30
      spinal cord dorsal horn anatomy with, 328–29, 329f
Index

pharmaceuticals for, 352–53
acetylsalicylic acid, 352
acetaminophen, 352
amantadine, 352
gabapentin, 352
nonsteroidal antiinflammatory drugs, 352
opioids, 352
tramadol, 352–53
physical therapy for, 354–55, 355f
physiologic signs of, 336–37
polysulfated glycosaminoglycans for, 353
postsurgical, 351f
regenerative stem cell therapy for, 355
Palpation of arteries, 102, 102f
Palpebral reflex, 101
PaO₂. See Partial pressure of oxygen
Partial pressure of carbon dioxide (PaCO₂), 92
Partial pressure of oxygen (PaO₂), 92
Patent ductus arteriosus (PDA), 210–11, 214t
Pathologic pain, 325–26
Patient recovery, 159–66
analgesia for, 165
anesthesia recovery with, 224
bandage placement with, 164
bedding for, 166
body temperature with, 163
heating elements for, 163, 163f
endotracheal tube extubation for, 165–66
ferrets in, 316
geriatric patients in, 281
monitoring patient during, 162–63, 163f
nasal oxygen placement with, 163–64
procedures overview for, 159–61
prolonged recovery from anesthesia, 184
rabbits in, 319
recovery room with, 161–62, 162f
regurgitation during, 165
removing monitoring equipment with, 162
rodents in, 319
tracheostomy patient, 164
tranquilization for, 165
transferring recovering patient with, 162
urinary catheter management in, 164–65
PCV. See Packed cell volume
PDA. See Patent ductus arteriosus
Peak Inspiratory Pressure (PIP), 189–90
Pediatric patients, 267–73
induction for, 269–72, 270t
alfaxalone, 270t, 271
etomidate, 270t, 271
inhalation agents for, 271, 271f
ketamine, 270, 270t
propofol, 269, 270t
maintenance for, 271–72
monitoring for, 272–73, 273f
physiology with, 267–68
postanesthesia for, 273
preanesthesia preparation for, 268, 268f
premedication for, 268–69, 270t
acepromazine, 269, 270t
alpha-2 agonists, 269
anticholinergics, 269, 270t
benzodiazepine, 269, 270t
opioids, 268–69, 270t
thermoregulation for, 272
PEEP. See Positive end expiratory pressure
Percentage calculations, 30
Percent solution calculations
agent strength, 30
preparing, 32
Perfusion pressure, renal system, 246
Perianesthetic arrhythmias, 213–16
pH, 92
Phenobarbital, 16–17
Phenothiazines, 136
cardiovascular effects from, 215t
cerebral blood flow with injectable, 222
liver disease pharmacology with, 259
renal disease anesthesia with, 251, 253t
Photoplethysmographic methods, 111
Physical therapy, pain management with, 356–57, 355f
Physiologic pain, 325–26
PIP. See Peak Inspiratory Pressure
Platelet count, 23
Polysulfated glycosaminoglycans (PSGAG), 353
Position of eye, 101
Positive end expiratory pressure (PEEP), 9, 190
Positive pressure ventilation (PPV), 9
PPV. See Positive pressure ventilation
PRBC. See Packed red blood cells
Preanesthetic preparation, 41–48
check equipment/monitor setup in, 41
check vaporizer in, 42
crash cart made available in, 44
endotracheal tube chosen for, 43
IV supplies preparation, 43–45
premedication/induction agent labeling in, 43
preparation for induction in, 43, 43f
pressure check anesthesia machine in, 41, 42f
squeeze out rebreathing bag in, 41, 42f
surgery room setup in, 45
OR table setup in, 46–47, 46f
cardiovascular drugs, 16
chemotherapy drugs, 16
insulin, 17

adjuvant analgesics drugs, 16
analgesics, 16
antibiotics, 16
anaesthetic workup, 13–26, 14f
ASA status, 20–21, 21f
current medication knowledge in, 16–17

thermoregulatory support preparation in, 46
nonsteroidal antiinflammatory drugs, 16
organophosphates, 17
phenobarbital, 16–17
diagnostics, 21–22
ALT, AST, and alkaline phosphatase serum tests, 22
arterial blood gases, 24
blood glucose, 22
Buccal mucosal bleeding time, 23
BUN serum test, 22, 249
coaulation profile, 22
complete blood count, 22
creatinine serum test, 22, 249
electrocardiogram, 24
endocrine testing, 24
full chemistry profile, 22
full urinalysis, 23–24
packed cell volume, 22
platelet count, 23
thrombocytopenic count, 23
total plasma protein, 22
urine specific gravity, 22
diagnostics imaging, 24
radiography, 24
ultrasound, 24
flow chart for, 14f
influencing factors with, 13–16
physical exam in, 17–20
  cardiovascular system, 17–18, 25f
  endocrine system, 20, 25f
  gastrointestinal system, 19, 25f
  hepatic system, 19, 25f
  integument system, 19–20, 25f
  nervous system, 19, 25f
  overall body condition, 20, 20f
  renal system, 18, 25f
  respiratory system, 18, 25f
SOAP for, 24, 26f
Preemptive analgesia, 348
Pregnancy. See also Cesarean section techniques
  physiological alterations in, 283–84
Premature ventricular contraction. See Ventricular premature contraction
Premedication drugs, 135–42
  acepromazine, 136, 137t
  alpha-2 agonists, 137–38
  anticholinergics, 136
  atropine, 136, 137t
  benzdiazepines, 136–37
  buprenorphine, 139
  butorphanol, 137t
  butyrophenones, 136, 137t
  combination does, 140–42
    BAG (butorphanol, acepromazine, glycopyrrolate), 140–41, 140f
    BMG (butorphanol, midazolam, glycopyrrolate), 140f
    HAG, 141
    KBAG, 141, 141f
    KHAG, 141, 141f
    Kitty Magic, 141–42
    O’BAG, 140, 140f
dexmedetomidine, 137t, 138
diazepam, 136–37, 137t
dissociative drugs, 138–39
fentanyl, 137t, 139
glycopyrrolate, 136, 137t
hydromorphine, 137t, 139
ketamine, 137t, 138–39
medetomidine, 137t, 138
methadone, 137t, 139
midazolam, 136–37, 137t
morphine, 137t, 139
naloxone, 139
opioids, 139–40
oxymorphine, 137t, 139
phenothiazines, 136
protocol for, 136
tiletamine, 138
tiletamine (Telazol), 137
tranquilizers, 136–37
xylazine, 137t, 138
zolazepam, 136–37
Preoperative evaluation from, 36f
Pressure cycled ventilator, 191
P-R interval, 4
Prolonged life support, cardiopulmonary/cerebral resuscitation with, 182–83
Propofol (Diprivan, Rapinovet)
  cardiovascular effects from, 215t
  cerebral blood flow with injectable, 222
  induction with, 146–47, 147t, 150t
  liver disease pharmacology with, 260
  pediatric patients induction with, 269, 270t
  renal disease anesthesia with, 252, 253t
PSGAG. See Polysulfated glycosaminoglycans
Pulmonic stenosis, 211–12, 214t
Pulse oximetry
  equine anesthesia maintenance with, 369
  factors influencing accuracy of, 96
  interpretation of data from, 97
  monitoring with, 95–97
  patient assessment/treatment of decreased SpO₂ with, 97
  physiology with, 95–96
  types of, 96
    reflectance probe, 96
    transmittance probe, 96, 96f
  working of, 95–96
PVC. See Ventricular premature contraction
P wave, 4, 86
Pyometra, 310

QRS complex, 4, 86
Q-T interval, 4

Rabbits, 319–22
anesthesia induction, care and support for, 320–22, 322f
anesthesia preparation for, 319–20
anesthesia recovery with, 322
emergency considerations for, 322
signs of acute pain in, 335f

Radiography, 24

Rapinovet. See Propofol

Ravi-Ricci return-to-flow principle, 111, 112

Rebreathing system, 80–81, 81f
pediatric circles in, 81
standard adult circles in, 81

Record keeping, 35–39
anesthetic record, 35–37, 36f
automated, 37
handwritten monitoring grid, 37
information included in, 35
legal document, 37
controlled substances, 37–39, 39f
preoperative evaluation from, 36f

Reexpansion pulmonary edema (RPE), 190

Referral pain, 329

Reflectance probe, 96

Regenerative stem sell therapy (RSCT), 355

Regurgitation, recovering patient with, 165

Renal disease, 245–54
anesthesia for, 250–54, 253t, 254t
alpha-2 agonists, 251, 253t
anticholinergics, 251, 253t
barbiturates, 252, 253t
benzodiazepine, 251, 253t
COX inhibition, 254, 254t
nitrous oxide, 252, 253t
nonsteroidal antiinflammatory drugs (NSAID), 252–54, 253t
opioids, 251, 253t
phenothiazine, 251, 253t
propofol, 252, 253t

Renal system
acid-base balance in, 249
anatomy of, 245–46, 246f
antidiuretic hormone in, 248–49
autoregulation in, 246
blood flow of, 246
juxtaglomerular apparatus in, 246–47, 248f
perfusion pressure in, 246
preanesthetic workup exam for, 18, 25f
renal function tests for, 249–50, 250t
blood urea nitrogen, 249
glomerular filtration rate, 249
serum creatinine, 22, 249
renin-angiotensin system, 246–48, 247f, 248f
Renin-angiotensin system, 246–48, 247f, 248f
Replacement fluid therapy, 126–27, 126f, 126t

Resistance, 189

Respiratory-challenged patients, 227–36
brachycephalic breeds’ concern with, 231–32, 231f, 232f
desaturation with, 233–34
induction for, 229–30, 230t, 231t
fentanyl, 231t
hydromorphone, 231t
ketamine, 230t, 231t
lidocaine, 230t, 231t
morphine, 230t
oxymorphone, 231t
intrathoracic surgery for, 232–33
premedication for, 228–29
recovery/postop analgesia for, 234–36, 235t–236t, 236f
wound soaker protocol for, 235t–236t, 236f

Respiratory rate, 188

Respiratory system, 7–11
anatomic dead space of, 9, 10f
anatomy of, 7–11, 8f, 10f
alveolar-capillary membrane, 8
alveoli, 7, 8f
bronchi, 7
bronchioles, 7
capillaries, 8
dead space ventilation of, 9, 10f
positive end expiratory pressure of, 9
positive pressure ventilation of, 9
preanesthetic workup exam for, 18, 25f

Resuscitation fluid therapy, 127

Retrobulbar block, 198

Rodents, 317–19
anesthesia induction, care and support for, 318–19, 319f
anesthesia preparation for, 317–18
anesthesia recovery with, 319
emergency considerations for, 322
signs of acute pain in, 335f

RPE. See Reexpansion pulmonary edema
RSCT. See Regenerative stem sell therapy

Ruminant anesthesia, 373–84
intravenous regional anesthesia for, 376–77
digital blocks in cattle, 377
peroneal/tibial nerve blocks, 377
local analgesia/nerve blocks for, 374–76
auriculopalpebral nerve block, 374
caudal block, 375
Index 401

cornual nerve block, 374–75, 375f
epidural block, 375–76
preanesthetic preparation for, 378–84, 379t, 380f, 384f
sedatives/sedation agents for, 377–78

SA node. See Sino-atrial node
SaO₂. See Oxygen saturation
SCr. See Serum creatinine
Sedation drugs, 135–42. See also Premedication drugs
Semiclosed circle systems, 84
Serum creatinine (SCr), 22, 249
Sevoflurane, 157–58, 157f
  cardiovascular effects from, 215t
  inhalant anesthetics for ICP with, 223
  minimum alveolar concentration of, 154t
  vaporization pressure of, 155t
Shock, 301–3
  cardiogenic, 130
  hypovolemic, 130
  obstructive, 130
Sidestream (diverting) monitor, 114–19
Sino-atrial node (SA node), 3
Sinus bradycardia, 88–89
Sinus tachycardia, 88, 88f
Smoke inhalation, 295–96, 296f
SOAP, 24, 26f
Sodium bicarbonate, cardiopulmonary/cerebral resuscitation with, 180t
Solubility coefficient, 155, 155t
Somatic pain, 328–29
Stroke volume, 106, 106f
Stylet and guide tubes, 62–63, 62f
Subaortic stenosis, 210f
Supraventricular arrhythmias (SVT), 213, 217t
SVT. See Supraventricular arrhythmias
Swallowing reflex, 101
Systemic vascular resistance, 6
Systolic blood pressure, 5, 6, 106, 107t

Tachycardia
  anesthesia complicated by, 173
  sinus, 88, 88f
  ventricular, 90–91, 90f, 173–74
Telazol. See Tiletamine
Therapeutic laser, pain management with, 354, 354f
Thiobarbiturate (Thiopental)
  cardiovascular effects from, 215t
  induction with, 148–49
Thiopental. See Thiobarbiturate
Thoracic trauma, 295
Thoracotomies, 227–36
  brachycephalic breeds’ concern with, 231–32, 231f, 232f
  desaturation with, 233–34
  induction for, 229–30, 230t, 231t
  fentanyl, 231t
  hydromorphone, 231t
  ketamine, 230t, 231t
  lidocaine, 230t, 231t
  morphine, 230t
  oxymorphone, 231t
  premedication for, 228–29
  recovery/postop analgesia for, 234–36, 235t–236t, 236f
  wound soaker protocol for, 233t–234t, 234f
Thrombocytopenic count, 23
Tidal volume, 9, 188
Tiletamine (Telazol), 137, 138
  induction with, 145–46, 147t, 150t
Time cycled ventilator, 191–92, 192f
TIVA. See Total Intravenous Anesthesia
Tolazoline-zolazepam, equine induction phase with, 365
Total Intravenous Anesthesia (TIVA), 363–66
Total peripheral resistance, 106
Total plasma protein, 22
Tracheal trauma, 294, 294f
Tracheostomy, patient recovery with, 164
Tramadol
  adaptive pain management with, 350
  pain management with, 352–53
Tranquilization, recovering patient with, 165
Tranquilizers, 136–37
Transcellular fluid, 123
Transfusions, 133–34, 133f
Transmittance probe, 96, 96f
Trauma patients, 293–300
  case report for, 297–300, 298t
  induction agents for, 296–97, 297t
  types of trauma for, 294–96, 294f, 296f
  blunt force trauma, 296
  burn injuries/smoke inhalation, 295–96, 296f
  ocular trauma, 294
  thoracic trauma, 295
  tracheal trauma, 294, 294f
Tricuspid valve, 4
T wave, 4, 86, 87f

Ultrasonography, 24
  Doppler, 111
Urethral obstruction, 309–10
Urinalysis, 23–24
Urinary catheter, recovering patient with, 164–65
Urine specific gravity (USG), 22
USG. See Urine specific gravity

Valium. See Diazepam
Vaporization pressure, 155, 155t
  desflurane, 155t
  halothane, 155t
isoflurane, 155t
sevoflurane, 155t

Vaporizers, 73–75, 74f, 75f
complications with, 168

Vasopressin, cardiopulmonary/cerebral resuscitation
with, 179, 180t

Vecuronium, cerebral blood flow with injectable,
222–23

Ventilation, 8
cardiac disease patient outcome with, 206
common terms with, 188–91
atelectasis, 8, 189
compliance, 189
functional residual capacity, 189
hyperventilation, 116f, 172, 188
hypocapnia, 188
hypoventilation, 115f, 171, 188–89
hypoxemia, 10, 172, 189
intermittent positive pressure ventilation, 188
resistance, 189
respiratory rate, 188
tidal volume, 9, 188
V/Q mismatch, 189
discontinuing support for, 194
equine anesthesia with, 371
equipment definitions with, 189–91
controlled ventilation, 189
inspiratory to Expiratory Ratio (I:E ratio),
190, 190f, 191
peak Inspiratory Pressure (PIP), 189–90
positive end expiratory pressure (PEEP), 9, 190
reexpansion pulmonary edema (RPE), 190
evaluation of efficiency with, 194
goals of, 187
manual v. mechanical, 187–88
presetting, 192–94
pressure testing for, 192–94
setup for, 192–94
techniques in small animal patients, 187–94
types of, 191–92
pressure cycled, 191
time cycled, 191–92, 192f
volume cycled, 191, 191f

Ventricular fibrillation (V-fib), 91
anesthesia complicated by, 173–74

Ventricular premature contraction (VPC), 90, 213, 217t
anesthesia complicated by, 173–74

Ventricular tachycardia (V-tach), 90–91, 90f, 217t
anesthesia complicated by, 173–74

Versed. See Midazolam

Vetalar. See Ketamine

Vetalar, Ketalean. See Ketamine

V-fib. See Ventricular fibrillation

Visceral pain, 326–27

WAG. See Waste anesthetic gas

Waste anesthetic gas (WAG)
active system for, 76–77, 76f
passive system for, 76
removal equipment, 76–77, 76f
troubleshooting, 78

Weight loss, pain management with, 356
Whole blood, 130, 130f
Withdrawal reflex, 101, 101f

Xylazine, 137t, 138
equine preanesthetic sedative with, 362

Zolazepam, 136–37
induction with, 145, 147t, 150t